- Sonnet BioTherapeutics Holdings Inc SONN says that the safety of SON-1010 dosing in several cohorts has been formally reviewed in both Phase 1 trials.
- The adverse events have generally been mild/moderate, transient in nature, and have all been tolerable. In addition, they have been less numerous and less intense with subsequent doses.
- There was minimal/no signal for IL-1β, IL-6, IL-8, or TNFα and no indication of cytokine release syndrome (CRS). IL-10 was also induced at a low level, as expected.
- Related: Sonnet BioTherapeutics Shares Jump After Janssen Pact For Its Three Product Candidates.
- Five of the six patients had stable disease at the first follow-up scan, with one patient progressing who is now off study. Investors are may be reacting to this.
- As of the most recent scan, 2 of the five stable disease patients remain stable, while the others had tumor growth that may represent tumor inflammation or unconfirmed progression.
- One endometrial stromal sarcoma patient progressing at study entry has evidence of improvement after six months on SON-1010 with smaller tumors and complete resolution of ascites.
- Price Action: SONN shares are down 27.40% at $2.06 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.